Advertisement

Allergo Journal

, Volume 27, Issue 6, pp 31–35 | Cite as

Placebo effects in allergen immunotherapy: an experts’ opinion

  • Anthony J. Frew
  • Oliver Pfaar
Mini-Review

Abstract

Placebo effects are common in medicine. Randomised clinical trials help us to understand their magnitude in different therapies. There are particular problems with placebo effects in allergen immunotherapy (AIT) as it is difficult to blind the active treatment and the endpoints are largely subjective. This may explain why large placebo effects are often found in AIT trials. Patients receiving open label AIT get the benefit of the active and placebo components but it can be difficult to say how much benefit is due to the active component. The use of active placebos has been proposed but brings its own problems (ethical and scientific). An EAACI Task Force has been established to address these issues. Here we review the current literature on the placebo effect in general, with a special focus on AIT trials, and indicate what we believe to be important considerations and unmet needs in AIT trial design.

Keywords

sublingual subcutaneous clinical trials endpoints EAACI task force 

Abbrevations

AIT

Allergen immunotherapy

DBPC

Double-blind, placebo-controlled

EAACI

European Academy of Allergy and Clinical Immunology

QoL

Quality of life

SCIT

Subcutaneous immunotherapy

SLIT

Sublingual immunotherapy

SPIRE

Synthetic peptide immunoregulatory epitopes

TF

Task Force

References

  1. 1.
    Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011;36:339–54CrossRefGoogle Scholar
  2. 2.
    del Cuvillo A, Sastre J, Bartra J, Mullol J, DaVila I, Montoro J, et al. Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol 2011;21(Suppl 3):40–5PubMedGoogle Scholar
  3. 3.
    Wedi B, Wieczorek D, Kapp A. Placebo effect in clinical trials with allergen-specific immunotherapy with inhalant allergens. Hautarzt. 2017;68:297–306CrossRefGoogle Scholar
  4. 4.
    Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013;3:42CrossRefGoogle Scholar
  5. 5.
    The European Agency for the Evaluation of Medicinal Products (EMA). ICH E 9: note for guidance on statistical principles for clinical trials (CPMP/ICH/363/96). 1998Google Scholar
  6. 6.
    Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy 2014;69:854–67CrossRefGoogle Scholar
  7. 7.
    Freeman J. Lancet 1914;2:814Google Scholar
  8. 8.
    Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component Lancet. 1954;266:1055–7CrossRefGoogle Scholar
  9. 9.
    Lowell FC, Franklin W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med 1965;273:675–9CrossRefGoogle Scholar
  10. 10.
    Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434–40CrossRefGoogle Scholar
  11. 11.
    Pfaar O, Bonini S, Cardona V, Demoly P, Jakob T, Jutel M, et al. Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 2018;73(Suppl 104):5–23CrossRefGoogle Scholar
  12. 12.
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergic drugs. Br Med J 1991;302:265–9CrossRefGoogle Scholar
  13. 13.
    Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Clinical efficacy and safety of specific allergy vaccination with Alutard Grass in seasonal allergic rhinoconjunctivitis: a large-scale randomised double-blind placebo-controlled multi-centre study (UKIS—The UK Immunotherapy Study). J Allergy Clin Immunol 2006;117:319–25CrossRefGoogle Scholar
  14. 14.
    La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425–32CrossRefGoogle Scholar
  15. 15.
    Varney VA, Edwards J, Mavroleon G, Brewster H, Tabbah K, Frew AJ. Clinical effects of desensitisation to cat dander: a double blind placebo-controlled trial. Clin Exp Allergy 1997;27:860–7CrossRefGoogle Scholar
  16. 16.
    Circassia Pharmaceuticals Inc. Circassia announces top-line results from cat allergy phase III study. 2016. https://www.circassia.com/media/press-releases/circassia-announces-top-line-results-from-cat-allergy-phase-iii-study Accessed 10 March 2018
  17. 17.
    Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larché M, et al. Fel d 1—derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013;131:103–9CrossRefGoogle Scholar
  18. 18.
    Pfaar O, Alvaro M, Cardona V, Hamelmann E, Moesges R, Kleine-Tebbe J. Clinical trials in allergen immunotherapy: current concepts and future needs. Allergy. 2018; https://doi.org/10.1111/all.13429CrossRefGoogle Scholar
  19. 19.
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:4–12CrossRefGoogle Scholar
  20. 20.
    Frew AJ, Smith HE. Sublingual immunotherapy. J Allergy Clin Immunol. 2001;107:441–4CrossRefGoogle Scholar
  21. 21.
    Smith HE, White PJ, Annila I, Poole J, Andre C, Frew AJ. Randomised controlled trial of high dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004;114:831–7CrossRefGoogle Scholar
  22. 22.
    Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317–24CrossRefGoogle Scholar
  23. 23.
    Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009;39:1786–800CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Respiratory MedicineRoyal Sussex County HospitalBrightonUK
  2. 2.Brighton & Sussex Medical School, Royal Sussex County HospitalUniversity of Sussex and University of BrightonBrightonUK
  3. 3.Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty MannheimHeidelberg UniversityMannheimGermany
  4. 4.Center for Rhinology and AllergologyWiesbadenGermany

Personalised recommendations